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Abstract: Among numerous drug-delivery approaches, reconstituted high-density   lipoprotein 
(rHDL) nanocarriers have proven particularly applicable for delivering highly   hydrophobic 
drugs. In this study, we have investigated the enhancement of the therapeutic impact of val-
rubicin (AD-32), an antineoplastic agent that has been limited to intravesicular   application 
against bladder cancer, despite the encouraging original preclinical data.   Earlier   studies 
  validated the superior therapeutic efficacy of AD-32 over doxorubicin. In the   present study, 
rHDL/AD-32 nanoparticles were formulated and characterized with regard to   encapsulation 
efficiency, physicochemical properties, selective toxicity, and receptor-mediated uptake. The 
half maximal inhibitory concentration values (IC50) for rHDL/AD-32 nanoparticles were 1.8 
and 2.6 times lower than the free AD-32 for prostate (PC-3) and ovarian (SKOV-3) cancer 
cell lines, respectively, whereas nonmalignant cell lines demonstrated 5 and 1.48 times 
higher IC50 doses with rHDL/AD-32 formulations. The data obtained demonstrated effective 
  receptor-mediated uptake of AD-32 from the rHDL nanocarriers by PC-3 and SKOV-3   cancer 
cells via a targeted drug-delivery process. The rHDL/AD-32 formulation was stable for 6 
months when stored at 4°C or at –20°C, as 92% of the AD-32 was retained in the nanopar-
ticles. The findings from this study show that the rHDL/AD-32   formulation can overcome 
the solubility barriers of AD-32 and thus serve as an effective systemically administered 
chemotherapeutic agent.
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Introduction
Drug delivery via nanotechnology is one of the vanguards of the rapidly expanding 
field of cancer therapeutics.1–3 A variety of submicron drug carrier systems have 
been developed recently to improve the delivery and retention of pharmaceuticals 
by malignant cells and tumors.4,5 Lipid-containing nanoparticles (LNs) represent an 
alternative delivery system to traditional carriers, such as emulsions, liposomes, and 
polymeric nanoparticles, especially for the delivery of lipophilic drugs.5,6 While LNs 
have several advantages over other formulations, they also have serious limitations 
such as nonselective toxicity, instability, and limited drug payload.6–8 Encapsulation of 
drugs within the reconstituted high-density lipoprotein (rHDL) nanocarriers has shown 
great potential for cancer chemotherapy by minimizing limitations encountered with 
conventional formulations, including LNs and liposomes.9–11 The rHDL nanoparticles 
have been identified as an effective drug-delivery system for highly lipophilic drugs11–13 
and for small interfering RNA (siRNA).14 The proof of concept studies using rHDL 
nanoparticles loaded with paclitaxel, dilauryl-fluorescein, and siRNA have shown that 
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the delivery of the drug to cancer cells and tumors occurs 
via a targeted, receptor-mediated mechanism involving the 
scavenger receptor class B type 1 (SR-B1).13–16
The current study was undertaken to evaluate the 
in vitro therapeutic efficacy of valrubicin [AD-32 
(N-  trifluoroacetyladriamycin-14-valerate)], a derivative of 
doxorubicin, which was originally developed as a cancer 
therapeutic agent,17–19 leading to its restricted approval for 
treating Bacillus Calmette-Guerin (BCG)–resistant bladder 
cancers in 1998.20,21 Even though AD-32 has been found to 
be much less toxic to normal tissues16,22 than doxorubicin 
during preclinical studies, its therapeutic application has 
been confined to nonsystemic administration due to its poor 
water solubility. This restriction remains in place except for 
recent attempts to extend the application of AD-32 to treat 
skin cancer and psoriasis via topical formulations.23,24 The 
highly hydrophobic nature of AD-32 and its proven anti-
neoplastic properties make it a promising candidate to serve 
as an effective chemotherapeutic agent when used in conjunc-
tion with the rHDL nanoparticles as delivery vehicles. In our 
present work, we formulated AD-32 with rHDL nanocarriers 
using the cholate dialysis technique.13 These particles were 
then characterized for their encapsulation efficiency and 
physicochemical properties. The rHDL/AD-32 nanocarri-
ers were also evaluated for their effect on cell viability in 
malignant prostate (PC-3) and ovarian (SKOV-3) cell lines, 
and nonmalignant prostate (PZ-HPV) and ovarian (HiO 180) 
epithelial cells. Drug uptake through the SR-B1 receptors, 
the in vitro release profile, and the stability of formulations 
were also studied in detail.
Materials
Sodium cholate, egg yolk phosphatidyl choline (PC), free 
cholesterol, cholesteryl oleate, potassium bromide (KBr), iso-
propyl thiogalactoside (IPTG), dimethyl sulfoxide (DMSO), 
Triton X-100, and thrombin cleavage kit were purchased 
from Sigma-Aldrich Corporation, St Louis, MO. NZYCM 
was obtained from Teknova, Hollister, CA. Bacterial protein 
extraction reagent and bicinchoninic acid (BCA) protein 
assay kits were purchased from Thermo Scientific, Rockford, 
IL. A histidine-trap (His-Trap) affinity column was obtained 
from QIAGEN, Valencia, CA. Cholesterol and phospholipid 
estimation kits were obtained from Wako Pure Chemical 
Industries Ltd, Richmond, VA. Roswell Park Memorial Insti-
tute 1640 media, keratinocyte media and fetal bovine serum 
were obtained from Gibco, Invitrogen, Carlsbad, CA. AD-32 
was provided by Dr Mervyn Israel, University of   Tennessee 
Health   Science Center, Memphis, TN. Low protein binding 
durapore membrane syringe filters were purchased from 
Millipore Ltd,   Billerica, MA.   Established cancer cell lines 
PC-3, SKOV-3, and PZ-HPV were obtained from American 
Type Culture Collection (ATCC), Manassas, VA. The ovar-
ian epithelium cell line HiO 180 was provided by Dr Anil 
K Sood of MD Anderson Cancer Center, Houston, TX. The 
cell counting kit (CCK-8) was purchased from Dojindo 
Laboratories, Tabaru, Japan.
Methods
Preparation of the AD-32 containing 
nanoparticles
Isolation and purification of recombinant apoA-I
These were performed essentially as described by 
Ryan et al.25 Briefly, BL21(DE3)pLysS cells bearing the 
pNFXex   plasmid were cultured in 500 mL NZYCM media 
(+50 µg/mL   ampicillin) at 37°C. When the culture optical 
density reached 0.6 at 600 nm, apoA-I synthesis was induced 
by the addition of IPTG to a final concentration of 0.5 mM. 
After 3 hours, the bacteria were pelleted by centrifugation 
and disrupted by lysis buffer (bacterial protein extraction 
reagent). The cell lysate was centrifuged at 20,000 g for 
30 minutes at 4°C. The supernatant fraction was mixed 
with an equal volume of phosphate-buffered saline (PBS) 
containing 6 M guanidine hydrochloric acid (HCl), applied 
to a 5 mL bed volume His-Trap affinity column, and purified 
as per manufacturer’s instructions. The N-terminal His-Tag 
extension was removed using a thrombin CleanCleave kit 
(Sigma-Aldrich). The isolated apo A-I was then dialyzed 
against tris(hydroxymethyl)aminomethane (Tris)-buffered 
saline containing 1 mM benzamidine for 16 hours at 4°C. 
The dialyzed sample was filter-sterilized (0.2 µm) and stored 
at 4°C until use.
Preparation of rHDL/AD-32 complexes  
with apo A-I
This was accomplished by a procedure developed earlier in our 
laboratory.10,13 Briefly, a mixture of egg yolk PC in CHCl3 with 
free cholesterol (FC), and cholesteryl oleate (CE), was prepared 
with a molar ratio of ApoA1:FC:CE:PC = 1:5:1.3:1.15 M.   
The lipid mixture (PC, FC, and CE) and the drug (AD-32) 
were dried under N2 to a thin film and dispersed in 60 µL 
DMSO. To this mixture, apo A-I (5 mg) and 140 µL sodium 
cholate (from a stock of 100 mM) were added and the volume 
was made up to 2 mL with Tris-ethylenediaminetetraacetic 
acid (EDTA) buffer (10 mM Tris, 0.1 M KCl, 1 mM EDTA 
pH 8.0). (Final PC to cholate molar ratio was maintained at 
∼1:1.6). The lipid/protein/cholate mixture was then incubated 
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for 12 hours at 4°C, followed by dialysis against 2 L of PBS, 
for 48 hours, with three buffer changes in the first 12 hours. 
The preparations were then centrifuged at 1000 rpm for 
2 minutes and sterilized using a 0.2 µm syringe filter. The 
preparations were kept in the dark at 4°C until used.
Characterization of rHDL/AD-32 
nanoparticles
Chemical composition
Cholesterol and phospholipids were determined by   respective 
enzymatic reagent kits (cholesterol E and phospholipid C), 
using microtiter plate assays as per manufacturer’s   suggestions. 
Protein determinations were carried out using a BCA protein 
assay kit. The percentage drug incorporation was deter-
mined by fluorescence spectroscopic   measurements, in a 
Cary Eclipse Spectrofluorometer (Varian Inc, Mulgrave, 
Australia).
Determination of entrapment efficiency of AD-32  
in the rHDL/AD-32 nanoparticles
The drug entrapment efficiency (DEE) was determined by 
measuring the amount of AD-32 in the formulations before 
the cholate dialysis step mentioned earlier (initial drug) and 
after filtration (final drug incorporated). DEE was calculated 
using the following formula: DEE = {Drug concentration 
after dialysis/Drug concentration before dialysis} ×100.
Drug-loading studies with rHDL/AD-32 
nanoparticles
rHDL/AD-32 particles were prepared using increasing initial 
concentrations of AD-32 while keeping all other ingredients 
constant. Final drug concentration and DEE were calculated 
as described above.
Ultracentrifugation
KBr, 1.2 g/mL, was added to 3 mL of sample. The sample 
was layered with KBr solutions with the corresponding 
  designated densities (1 mL, 1.22 g/mL; 4 mL, 1.063 g/mL; 
and 3 mL, 1.019 g/mL) and centrifuged in an Optima LE 80K 
ultracentrifuge (Beckman Coulter, Brea, CA) for 36 hours 
at 39,000 rpm at 4°C using a swinging bucket rotor (SW 
40) in a Beckman.26 Fractions (1 mL) were collected cor-
responding to very low-density lipoprotein (fraction 1–2, 
P = , 1.007 g/mL); intermediate density lipoprotein (fraction 
3, P = 1.007–1.02 g/mL); low-density lipoprotein (fractions 
4–6, P = 1.020–1.060 g/mL); high-density lipoprotein (HDL)2 
(fractions 7–8, P = 1.060–1.15 g/mL): HDL3 (  fractions 
9–10, P = 1.15–1.235 g/mL) and lipoprotein deficient 
serum (  fractions 11–13, P . 1.235 g/mL), and subsequently 
analyzed for protein, phospholipid, and cholesterol.
Estimation of the size and morphology  
of rHDL/AD-32 nanoparticles
Dynamic light scattering (DLS)
Particle size analysis of the AD-32-loaded rHDL nanopar-
ticles was carried out using a Nanotrac system (Microtrac Inc, 
Montgomeryville, PA) as per manufacturer’s instructions. 
The nanoparticles were dispersed in aqueous buffer using an 
ultrasonic waterbath (Fisher Scientific, Pittsburgh, PA) for 
2 minutes and then measured for particle size.
The results were reported as the average of three indepen-
dent runs with duplicate observations in each run.
Atomic force microscopy (AFM)
The rHDL-AD-32 formulation was dialyzed at 4°C for 
12–18 hours against sterile distilled and deionized water to 
remove the salts from the solution. It was further diluted 1:5 
with sterile distilled water. Ten microliters of the sample was 
then placed on the microscope slide and was allowed to air 
dry. Sample was then processed with AFM on an NTEGRA 
Prima scanning probe microscope (NT-MDT, Santa Clara, 
CA). Closed-loop feedback semicontact mode was used at a 
rate of 0.6 Hz. Scanning started from the 50 µm area, going 
down to 5 µm. The images obtained were analyzed with NT-
MDT image analysis software (v 2.2). At least 25 individual 
particles were measured from three different positions and 
the average diameter was reported.
Transmission electron microscopy (TEM)
Following dialysis in a volatile buffer (0.125 M ammonium 
acetate, 2.6 mM ammonium carbonate, 0.26 mM EDTA, 
pH 7.4), the isolated rHDL samples were negatively 
stained with 2% sodium phosphotungstate, pH 7.2 and 
placed on Formvar/Carbon-coated 200 mesh nickel grid 
support films (Ted Pella Inc, Redding, CA) as previously 
described.27 The particles were visualized using a magni-
fication of 50,000 on a Zeiss 910 transmission electron 
microscope (Carl Zeiss, Thornwood, NY). The pictures 
were enhanced and the particle diameter determined with 
Adobe ImageReady CS2 software (Adobe Systems, San 
Jose, CA).
Effect of free and rHDL encapsulated 
AD-32 on cell viability
Culturing of the malignant prostate cancer cell line 
(PC-3), malignant ovarian cancer cell line (SKOV-3) and 
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  nonmalignant ovarian epithelial cell line (HiO180) were 
carried out according to procedures and culturing conditions 
provided by the ATCC.28,29 Briefly, the cells were cultured in 
Roswell Park Memorial Institute 1640 containing 2.05 mM 
L-glutamine and 10% fetal bovine serum. A nonmalignant 
prostate epithelial cell line (PZ-HPV) was grown in kerati-
nocyte medium supplemented with 10% fetal bovine serum 
medium containing human recombinant epidermal growth 
factor and bovine pituitary extract (both from Invitrogen) as 
per manufacturer’s instructions. All the cells were grown in 
75 cm2 flasks and incubated at 37°C and 5% CO2. Cells were 
passaged using 0.25% trypsin to release the cells from the 
flasks, once 80%–90% confluency was reached.
Preparation of drug formulations
A stock solution (50 mg/mL) of AD-32 in DMSO was 
prepared by emulsifying the drug in 50% sterile bovine 
serum albumin (BSA)/PBS by stirring. Samples for the 
characterization studies were prepared by diluting the stock 
with PBS to achieve equivalent AD-32 molar concentration 
to that contained by the respective rHDL/AD-32 nanoparticle 
samples. (The unencapsulated AD-32 suspension in BSA is 
referred to as “free drug.”)
Determination of IC50 doses
The effect of AD-32 in free drug and rHDL encapsulated 
particles was studied using CCK-8 kit (Dojindo Molecular 
Technologies, Tabaru, Japan).30 Briefly, the PC-3, SKOV-3, 
PZ-HPV , and HiO180 were grown according to procedures 
and culturing conditions provided by the ATCC in their 
respective media as stated earlier in 75 cm2 flasks and incu-
bated at 37°C and 5% CO2.
28,29 Cells were passaged using 
0.25% trypsin to release the cells from the flasks, once 
80%–90% confluency was reached. Cells were counted 
using hemocytometer and 5000 cells were seeded per well 
into 96-well microtiter plates and incubated at 37°C in 5% 
CO2 for 24 hours to allow the cells to attach to the plates. The 
free drug and the rHDL/AD-32 nanoparticles were diluted 
in serum-free medium to yield stock solutions of equivalent 
molar concentrations. Subsequently, aliquots of the stock 
solutions were added to microtiter plate wells to achieve the 
selected concentration range for the cell viability tests. Con-
trols included cells with media (without rHDL/drug), cells 
with empty rHDL particles, and media without cells with 
same rHDL/drug and free drug of each concentration used. 
Cells were incubated at 37°C in 5% CO2 for 24 hours. After 
incubation, 10 µL of highly water-soluble tetrazolium salt, 
WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] stock 
solution (Dojindo) was added to each well. After 3 hours of 
incubation at 37°C, the absorbance at 450 nm was measured 
using a Bio-Rad 3550 microplate reader (Bio-Rad Labora-
tories, Hercules, CA). Each concentration was studied with 
six replicates.
Monitoring the uptake of the drug 
payload from the rHDL/AD-32 complex
Cells were plated in 24-well plates (100,000 cells/well) in 
their respective media. On the following day, the monolay-
ers were washed with PBS, pH 7.4, and then incubated at 
37°C with serum-free medium for 90 minutes. Cells were 
washed with PBS and incubated with a single concentra-
tion of the rHDL/AD-32 complex plus increasing amounts 
of HDL (0–120 µg) in serum-free medium for 90 minutes. 
The preparation was washed once with 1 × PBS, pH 3.0, and 
subsequently with 1 × PBS, pH 7.4. The cells were then lysed 
with lysis buffer (50 mm Tris-HCl [pH 8.0], 150 mM NaCl, 
0.02% sodium azide, 100 µg/mL phenylmethanesulfonylfluo-
ride, 1 µg/mL aprotinin, and 1% Triton X-100). The lysate 
was centrifuged at 10,000 rpm for 5 minutes. The protein 
and AD-32 content of the lysate was determined by BCA 
assays and spectrophotometric measurements respectively 
as described above.
In vitro release studies
These were performed using a dynamic dialysis technique,31–33 
modified to maintain a sink condition for improved repro-
ducibility. A 2 mL sample of AD-32-rHDL preparation was 
transferred to a dialysis bag with molecular weight cut off 
of 6000–8000 MW and placed into the preheated dissolu-
tion medium at 37°C containing 100 mL of PBS at pH 7.4. 
The suspension was stirred at 37°C ± 0.5°C using a gyratory 
shaker at 50 rpm. Five hundred microliters of the sample was 
withdrawn at fixed time intervals and replaced with the same 
volume of fresh buffer. Samples were scanned using Cary 
Winuv scan software (v 3.00) in a Cary Varian UV-visible 
spectrophotometer (Agilent Technologies, Santa Clara, 
CA). Free AD-32 in pH 7.4 PBS was used as a control. All 
the operations were carried out in triplicate. The amount of 
AD-32 released from the dialysis bags were measured using 
a standard graph with a known concentration range of AD-32 
versus absorbance at 490 nm.
Stability studies
These were performed at 4°C and -20°C. The particles were 
stored at 4°C and 100 µL aliquots were removed at desig-
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nated time periods. The samples were dialyzed using dialysis 
tubing with an 8000 MW cut off at 4°C for 18 hours. The 
AD-32 content and particle size before and after dialysis were 
determined spectrophotometrically and by DLS methods 
respectively as described above.
Stability to lyophilization
rHDL/AD-32 particles were dialyzed against 0.1 M PBS. 
The nanoparticles were freeze dried at -46°C/0.5 Mbar in a 
Labconco freeze drier (Labconco Corp, Kansas City, MO) 
until they were completely dry, producing a powder. The 
freeze-dried preparations were stored at -20°C for 24 hours 
and then reconstituted in 1 × PBS. The AD-32 content and 
particle size before and after dialysis were determined spec-
trophotometrically and by dynamic light scattering methods 
respectively as described above.
Results
Characterization of rHDL/AD-32 
nanoparticles
Assembly of the AD-32-containing nanoparticles was achieved 
by the cholate dialysis procedure, developed earlier in our 
laboratory.13,15 As shown in Table 1, the predominant com-
ponent of the rHDL/AD-32 nanoparticles was phospholipid 
(62.0%), followed by protein (28.8%), cholesterol (0.96%) 
and AD-32 (8.3%). The phospholipid to protein ratio was 
2.15:1 for the drug-loaded nanoparticles as compared with 
1.96:1 for the empty particles (without drug). The entrapment 
efficiency of AD-32 in the rHDL nanoparticles was assessed 
by preparing particles with an increase in the initial concentra-
tion of AD-32 while keeping the amount and proportions of 
all the other components constant. As indicated in Figure 1, 
the entrapment efficiency of AD-32 decreased from 96% to 
32.7% with an increase in the initial concentration of AD-32 
from 0.5 mg/mL to 3 mg/mL. The highest amount of drug was 
incorporated at the initial concentration of 2 mg/mL.
The size of the rHDL/AD-32 nanoparticles was 
  determined using three methods: DLS, TEM, and AFM. 
The DLS data in Figure 2A depict a relatively narrow size 
distribution ranging from 29 to 120 nm with the mean 
particle size being 43.7 nm. The images obtained by AFM 
(Figure 2B) and TEM (Figure 2C) indicated the presence of 
spherical particles with a diameter ranging from 15 to 25 nm 
and mean particle size of 18 and 20 nm, respectively. The 
data from DLS show larger diameter particles (compared 
with the data from TEM and AFM) as it has during our 
previous studies with other drug-containing nanoparticles 
(unpublished data). The buoyant density pattern of the 
AD-32 containing rHDL preparation is shown in Figure 3 
as the distribution of fluorescence in a density gradient. 
The centrifugation pattern developed for the rHDL/AD-32 
particles shows a peak in fraction #8, coinciding with the 
position of circulating human HDL.
Determination of IC50
Cell viability assays (CCK-8) were performed using free 
AD-32, AD-32-loaded rHDL nanoparticles, and blank 
(empty) rHDL nanoparticles. Untreated cells and equivalent 
formulations without cells served as controls. The data for 
free AD-32 and AD-32 enclosed in rHDL nanoparticles 
depicted as the drug concentration required to inhibit cell 
growth by 50% (IC50), is shown in Table 2. The IC50 for the 
AD-32-loaded rHDL nanoparticles was found to be greater 
than 48 µM for both nonmalignant cell lines while the IC50 
values for the free AD-32 were substantially lower (9.5 µM 
and 32.5 µM, respectively). These data indicate that the 
encapsulation in the rHDL nanoparticles protects normal 
(nonmalignant cells) from the impact of cytotoxic drugs. The 
IC50 values for the rHDL-enclosed and free AD-32 samples 
for the PC-3 cells were 8.1 and 19.3 µM, respectively. 
A similar trend was observed for the SKOV-3 cells, where 
the IC50 for rHDL loaded AD-32 particles and free drug 
were 11.9 and 21.5 µM, respectively. These data show that 
Table 1 Chemical composition of rHDL/AD-32 particles
Type  
of particles
rHDL components mg/mL (%)
Protein Phospholipid Cholesterol AD-32
rHDL/AD-32 2.04 (28.8) 4.39 (61.9) 0.07 (0.96) 0.59 (8.31)
Empty rHDL 2.34 (33.4) 4.58 (65.3) 0.09 (1.31) 0
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
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Figure 1 Loading efficiency of AD-32 into rHDL nanoparticles via the cholate 
dialysis process (see methods for details).
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
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the encapsulation in the rHDL nanoparticles enhances the 
cytotoxic potential of AD-32 against malignant cells as we 
have shown earlier for paclitaxel.13
Uptake of AD-32 from rHDL particles  
by malignant and nonmalignant cells
Uptake of AD-32 by the PZ-HPV, PC-3 (prostate), HiO180, 
and SKOV-3 (ovarian) cell lines was assessed in the pres-
ence and absence of increasing amounts of human HDL 
(a competitor for the SR-B1 receptor).10,11,15 As shown in 
Figure 4, there was a substantial decrease in the uptake of 
AD-32 from the AD-32 containing rHDL nanoparticles 
by the malignant cells (PC-3 and SKOV-3), in response 
to the progressively increasing HDL concentrations in 
the incubation mix. The nonmalignant cells (PZ-HPV and 
HiO180), however, showed a much more limited response 
to increasing HDL, consistent with their lower expression 
of the SR-B1 receptor.10–12,14,15.
Stability studies of AD-32 loaded rHDL 
nanoparticles
As shown in Table 3, almost 90% of the AD-32 content 
of the rHDL nanoparticles was retained during 6 months 
storage at 4°C. Ninety-two percent of the  original AD-32 
was retained within the rHDL particles following 6 months 
storage at –20°C.   Lyophilization was found to be the best 
approach for sustained storage for the drug-containing rHDL 
nanoparticles. The mean diameter of the stored particles was 
found to be very close to that of the freshly prepared particles 
(Figure 2 and Table 3) indicating minimum aggregation upon 
rehydration from the powdered form.
In vitro release profile of AD-32-loaded 
rHDL nanoparticles
In vitro release studies were carried out by dynamic dialysis 
technique in a dialysis bag incubated at 37°C in PBS. About 
80% of the integrity of rHDL/AD-32 nanoparticles was 
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Figure 2 Estimation of the diameter of the AD-32 containing rHDL nanoparticles by (A) dynamic light scattering, (B) atomic force microscopy, and (C) transmission electron 
microscopy.
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Figure 3 Distribution of the AD-32 containing rHDL nanoparticles subsequent to 
preparative ultracentrifugation (see text for experimental details).
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
Table 2 Cytotoxicity of AD-32, delivered by rHDL nanocarriers 
versus the free drug against malignant and normal cells
Cell lines used IC50 for free  
AD-32 (μM)
IC50 for rHDL  
AD-32 (μM)
Nonmalignant
  PZ-HPV 9.5 .48
  HiO180 32.5 .48
Malignant
  PC-3 19.3 8.1
  SKOV-3 21.5 11.9
Note: 48 µM AD-32 was highest dose tested.
Abbreviations: PZ-HPV, nonmalignant prostate epithelial cell line; PC-3, prostate 
cancer cell line; HiO180, nonmalignant ovarian epithelial cell line; SKOV-3, ovarian 
cancer cell line; rHDL, reconstituted high-density lipoprotein.
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preserved up to 72 hours under these conditions. However, 
nearly 70% of the free drug was released within 8 hours and 
more than 90% of the drug was released after about 20 hours 
under the same dialysis conditions (Figure 5).
Discussion
AD-32 has been shown to have antineoplastic activity, low 
cardiotoxicity, and 24-fold higher lipophilicity than its par-
ent compound, doxorubicin.17–20 While the chemotherapeutic 
potential of AD-32 was recognized earlier during preclinical 
studies,17,18 its application has so far been limited to vesicular 
treatment of bladder cancer, primarily due to its poor water 
solubility.21,34 Here, we report an attempt to overcome this 
solubility barrier by encapsulating the AD-32 in rHDL 
nanoparticles.11–16
The advantageous characteristics of HDL-based drug car-
riers include small size, selective delivery via receptor target-
ing, stability during storage, and high payload capacity.11–16 
Encapsulation of lipophilic drugs within nanocarriers has 
shown great potential as an alternative or an adjunct to 
existing chemotherapy regimens.4,5 In addition, the selec-
tive targeting of malignant cells through receptor-mediated 
uptake of anticancer drugs13,14 is a key concept in mediating 
or eliminating the side effects of conventional chemotherapy. 
The present study was undertaken to evaluate the potential 
of AD-32 as a chemotherapeutic agent upon encapsulation 
into biocompatible rHDL nanoparticles.
The rHDL/AD-32 particles were prepared by cholate 
dialysis, producing macromolecular structures that resembled 
circulating HDL with respect to physical and chemical char-
acteristics. The rHDL/AD-32 nanoparticles, prepared  by 
cholate dialysis, exhibited physico-chemical properties simi-
lar to  that of native (circulating) human HDL10.16 Overall, 
these particles exhibited similar shape, size, and chemical 
composition to formulations of rHDL/dilauryl fluorescein 
and rHDL/paclitaxel particles, described earlier.13,15 The 
discrepancy in the size by DLS and other methods is likely 
to be due to the bias of the light scattering instrument toward 
larger particles. The key findings of this study are that AD-32 
could be efficiently encapsulated into rHDL nanoparticles 
yielding a stable (nonleaking) preparation that efficiently 
delivers its payload to cancer cells. A major advantage of the 
rHDL drug-delivery system is that the particles are composed 
of naturally occurring biodegradable ingredients found in 
the vascular system. Consequently, they are not likely to 
elicit any immunological response in the host. Thus, it is 
anticipated that the rHDL nanoparticles have a relatively 
extended residence time in the circulation (similar to HDL) 
compared with most traditional drug-delivery vehicles, 
including liposomes. These physicochemical properties 
of rHDL/AD-32 emphasize its candidacy as an effective 
delivery model for anticancer agents and other systemically 
administered drugs.
Doxorubicin alone or in combination with other drugs has 
been reported to be effective against a wide range of cancers 
including prostate, ovarian, and breast carcinoma.35,36 Despite 
its reduced cardiotoxicity, AD-32 has been mainly restricted to 
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Figure 4 Comparative drug uptake studies from rHDL/AD-32 nanoparticles with 
malignant and non-malignant ovarian and prostate cell lines.
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein; 
PZ-HPV, nonmalignant prostate epithelial cell line; PC-3, prostate cancer cell line; 
HiO 180, nonmalignant ovarian epithelial cell line; SKOV-3, ovarian cancer cell line; 
HDL, high-density lipoprotein.
Table 3   The  stability  of  AD-32/rHDL  particles  at  different 
storage conditions
Storage condition % drug recovery Mean diameter  
(minimum–maximum)
4°C for 6 months 89.9 ± 3.4 46.5 (32–130) nm
-20°C for 6 months 92.3 ± 2.8 48.3 (28–120) nm
Lyophilization  
(-46°C/0.5 Mbar)
94.6 ± 4.1 43.7 (30–121) nm
Abbreviations: AD-32, valrubicin; rHDL, reconstituted high-density lipoprotein.
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the treatment of bladder cancer. In order to evaluate the effi-
cacy of AD-32 in the treatment of prostate and ovarian cancer, 
we have examined its effects on malignant and nonmalignant 
cells of prostatic and ovarian origin. Nonmalignant cells of 
both the PZ-HPV and HiO180 lines were more sensitive to 
the free AD-32 than to the rHDL-encapsulated drug prepa-
ration, suggesting better protection against cytotoxic effects 
of the encapsulated drugs provided by the rHDL carrier for 
normal cells and tissues.14 The cancer cells, however, exhibited 
increased sensitivity to the rHDL encapsulated drug formula-
tion as compared with the cytotoxic effect of the free drug, 
probably due to the higher expression of the SR-B1 receptor 
in malignant cells.10–12,14,15 These observations are consistent 
with our earlier studies with other chemotherapeutic agents 
on malignant cancer cells.10–12,14,15 Additional studies were 
conducted to probe the delivery mechanism of AD-32 by 
evaluating the effect of added human HDL on the drug uptake 
by the malignant and nonmalignant cells. Earlier, we showed 
that the majority of the drug molecules are taken up from the 
rHDL nanoparticles by cancer cells via the SR-B1 receptor, 
whose normal function includes the extraction of cholesteryl 
esters from HDL.14,15 This receptor has been shown to be 
markedly overexpressed in malignant cells and tissues, appar-
ently because of their need for excess cholesterol, due to their 
high proliferative rates.10–12,14,15 A progressive decrease in the 
AD-32 uptake from rHDL nanoparticles was observed when 
the cancer cells were pre-incubated with human HDL. These 
findings suggest that the added HDL competes with rHDL 
for the receptor sites and that the uptake of AD-32 by cancer 
cells from rHDL nanoparticles is also facilitated by HDL/
SR-B1 receptors.11,15 Previous studies have demonstrated that 
accumulation of the siRNA (delivered via the rHDL nanopar-
ticles) was undetectable in nearly all normal tissues (except 
marginally in the liver) while it was substantial in tumor tissue, 
suggesting that selective drug delivery to tumors via rHDL 
is feasible.11,12,14 The selective tumor delivery concept would 
make the rHDL nanoparticles outstanding drug-delivery 
candidates for the purposes of reducing off-target effects and 
avoiding drug resistance during cancer chemotherapy.
The stability studies of rHDL/AD-32 particles under 
different conditions demonstrated the ease of storage of 
these particles for long-term use. In particular, the stability 
subsequent to lyophilization enhances the feasibility of the 
AD-32/rHDL drug-delivery system for clinical applications. 
Furthermore, in vitro drug-release studies carried out at 
physiological pH conditions emphasize nonleaky formula-
tions that could sustain these drug-loaded particles longer 
in circulation.
Conclusion
In this study, we prepared AD-32 containing rHDL nano-
particles that exhibited up to 96% entrapment efficiency and 
formed smooth, spherical particles with mean diameter size 
of 15–20 nm. The formulation was stable and nonleaking 
under several storage conditions. The findings from cyto-
toxicity and drug-uptake studies on malignant and normal 
(prostate and ovarian) cell lines suggest for the first time that 
the chemotherapeutic efficacy of AD-32 upon encapsulation 
in biocompatible nanoparticles may be markedly enhanced 
by the reduction (or elimination) of harmful side effects, 
due to selective tumor delivery of the anticancer agent, thus 
making it a potential candidate for alternate or adjuvant 
chemotherapeutic regimens.
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